Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG2025 in advanced malignant solid tumors
NCT05477849Phase 1Recruiting
- Sponsor
- Virogin Biotech
- Start
- Aug 2022
- Primary completion
- Oct 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VG2025 in advanced malignant solid tumor, sponsored by Virogin Biotech. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose at 28 days and Adverse Events and Serious Adverse Events at 12 months. Started Aug 2022; status: recruiting.
02
Drugs
VG2025
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT05477849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477849.